Form 4: Orchestra BioMed Holdings Director Eric S. Fain Acquires Shares and Stock Options

Director Eric S. Fain reports acquisition of common stock and stock options in Orchestra BioMed Holdings.

Summary

• On June 20, 2024, Eric S. Fain, a director of Orchestra BioMed Holdings, Inc., acquired 5,376 shares of common stock and 17,068 stock options.
• The common stock was acquired at a price of $0 per share.
• The stock options have an exercise price of $7.44 and expire on June 20, 2034.
• The restricted stock units (RSUs) vest on June 20, 2025.
• Following the transaction, Fain indirectly owns 46,810 shares of common stock through the Fain Living Trust.
• Fain also indirectly owns 17,068 derivative securities through the Fain Living Trust.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares and options by a director suggests confidence, but it's a routine filing.

Positives

• The acquisition of shares and stock options by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in the biopharmaceutical industry. Monitoring such transactions can provide insights into management's sentiment about the company's prospects.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates